Gyros Protein Technologies’ Immunoassay System to be Incorporated into Jefferson Institute for Bioprocessing’s Curriculum
The system, which works to miniaturize, integrate, and automate bioanalytical processes, will give JIB students enrolled in the school’s specialist graduate, PhD, and industry training programs the ability to enhance their industry skills via access to Gyrolab systems and ready-to-use kits.
Gyros Protein Technologies, a Mesa Laboratories company, and the Jefferson Institute for Bioprocessing (JIB) at Thomas Jefferson University, announced on March 16, 2020 that Gyros’ Gyrolab xPlore immunoassay system will be incorporated into JIB’s curriculum.
According to a Gyros press release, the system, which works to miniaturize, integrate, and automate bioanalytical processes, will give JIB students enrolled in the school’s specialist graduate, PhD, and industry training programs the ability to enhance their industry skills via access to Gyrolab systems and ready-to-use kits.
“It is essential our courses offer students the opportunity to train using technologies at the leading edge of the field,” said Dr Parviz Shamlou, executive director, Jefferson Institute for Bioprocessing, in the press release. “Real world experience of the Gyrolab platform and kits enable our researchers to graduate with advanced skills that add value in the biopharma industry.”
“While biologics constitute more than 40% of the pharmaceutical industry pipeline, only a few places around the world are dedicated to training the workforce to meet this demand,” added Dan Calvo, president of Gyros Protein Technologies, in the press release. “We are looking forward to working with JIB, a leading specialized training institute in the industry, to integrate Gyrolab technologies within their training programs.”
Source: Gyros Protein Technologies
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
